POPietro Oldrati

Pietro Oldrati

*This is an algorithmically generated author record based on publicly available information.

Pietro Oldrati has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Liliana Barrios

    Department of Computer Science, ETH Zurich, Zurich, Switzerland

    5 shared publications
  • Marc Hilty

    Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Hospital and University Zurich

    4 shared publications
  • Andreas Lutterotti

    From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Zürich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universitäts-Kinderspital Zürich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine,...

    3 shared publications
  • Andreas Lutterotti

    Cellerys AG, Wagistrasse 21, Schlieren, Switzerland

    3 shared publications
  • Christian Holz

    Department of Computer Science, ETH Zurich, Zurich, Switzerland

    3 shared publications
  • Marc Hilty

    Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zurich, 8091 Zurich, Switzerland

    3 shared publications

Latest Publications

  • Open Access

    Kupffer cells are key mediators of antigen-specific immune tolerance by peptide-coupled red blood cells

    by Vasileia Kalaitzaki, Pietro Oldrati, Filipa M. Ferreira, Antonios Katsoulas, Ahmed Ali, Livio Baselgia, Yun Liu, Jincheng Fang, Roman Sankowski, Mai Matsushita, et al.

    Induction of antigen-specific immune tolerance is the most precise method for reverting an autoreactive immune response in diseases such as multiple sclerosis (MS). Coupling red blood cells (RBCs) with a cocktail of MS immunodominant peptides is a promising approach to induce antigen-specific immune tolerance in patients. Here, we show that RBCs coupled with disease-inducing antigen efficiently prevent the development of experimental autoimmune encephalomyelitis, when administered prophylactically, and ameliorate disease symptoms when given therapeutically. The tolerogenic activity of peptide-coupled RBCs (pcRBC) was antigen specific and dependent on both cell and peptide dose. Kupffer cells (KC) were the primary phagocytes of pcRBC, and their uptake of pcRBC did not require complement component 3, SIRPα, and Stabilin 1 and 2. KC were indispensable for the induction of tolerance, which was accompanied by programmed death-ligand 1 up-regulation and a tolerogenic transcriptional shift. Our findings establish KC as central mediators of pcRBC-induced immune tolerance and provide mechanistic insight for the use of this therapeutic strategy in autoimmune disease.

  • Open Access

    Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells

    by Andreas Lutterotti, Thomas Ludersdorfer, María José Docampo, Muriel Morax, Helen Hayward-Koennecke, Pietro Oldrati, Vasileia Kalaitzaki, Zoe Marti, Angela Zaugg, Mattias Bronge, et al.

    Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial with clinical, imaging, and mechanistic readouts. RBCs coupled with seven immunodominant myelin peptides (pcRBCs) were safe and well tolerated. Several clinical and imaging readouts remained stable, which was supported by a reduction of neurofilament light chain indicating reduced tissue inflammation in the brain. Single-cell RNA sequencing identified expansion of antigen-specific CD4+ memory T cells with regulatory phenotypes and loss of proinflammatory cells three months after a single administration of pcRBCs. This was corroborated by a reduction of autoreactive CD4+ T cell responses and an early increase of IL-10, Tr1 regulatory T cells and tolerogenic monocytes and plasmacytoid dendritic cells. Biodistribution studies in mice and humans demonstrate that pcRBCs are rapidly processed by Kupffer cells in the liver and by marginal zone macrophages in the spleen. In summary, pcRBCs are a promising autologous cell therapy for achieving antigen-specific immune tolerance in MS.


  • Open Access

    Clinical and Immunologic Effects of Paraprobiotics in Long-COVID Patients

    by María José Docampo, Mattei Batruch, Pietro Oldrati, Ernesto Berenjeno-Correa, Marc Hilty, Gabriel Leventhal, Andreas Lutterotti, Roland Martin, Mireia Sospedra

    After the enormous health burden during the acute stages of the COVID-19 pandemic, we are now facing another important challenge, that is, long-COVID, a clinical condition with often disabling signs and symptoms of the neuropsychiatric, gastrointestinal, respiratory, cardiovascular, and immune systems. While the pathogenesis of this syndrome is still poorly understood, alterations of immune function and the gut microbiota seem to play important roles. Because affected individuals are frequently unable to work for prolonged periods and suffer numerous health compromises, effective treatments represent a major unmet medical need. Multiple potential therapies have been tried, but none is approved yet. Approaches that are able to influence the immune system and gut microbiota such as probiotics and paraprobiotics, i.e., nonviable probiotics, seem promising candidates. We, therefore, evaluated the clinical and immunologic effects of paraprobiotics in a small pilot study. A total of 6 patients with long-COVID were followed systematically for more than 12 months after disease onset using standardized validated questionnaires, a smartphone app, and wearable sensors to assess neurocognitive function, fatigue, depressiveness, autonomic nervous system alterations, and quality of life. We then offered patients defined paraprobiotics for 4 weeks and evaluated them at the end of the treatment period using the same questionnaires, smartphone app, and wearable sensors. In addition, a comprehensive immunophenotyping and gut microbiota analysis was performed before and after treatment. Improvements in several of the neurologic symptoms such as dysautonomia, fatigue, and depression were documented using both patient-reported outcomes and data from the smartphone app and wearable sensors. Of interest, the expression of activation markers on some immune cell populations such as B cells and nonclassical monocytes and the expression of toll-like receptor 2 (TLR2) on T cells were reduced after paraprobiotics treatment. Our results suggest that paraprobiotics might exert positive effects in patients with long-COVID most likely by modulating immune cell activation and expression of TLR2 on T cells. Further studies with paraprobiotics should confirm the promising observations of this small pilot study and hopefully not only improve the outcome of long-COVID but also unravel the pathomechanisms of this condition. This study provides Class IV evidence that paraprobiotics increase the probability of favorable changes of clinical and immunologic markers in patients with long-COVID.


  • Open Access

    Assessing the Role of the Autonomic Nervous System as a Driver of Sleep Quality in Patients With Multiple Sclerosis: Observation Study

    by Max Moebus, Marc Hilty, Pietro Oldrati, Liliana Barrios, PHRT Author Consortium, Christian Holz

    Background: Low sleep quality is a common symptom of multiple sclerosis (MS) and substantially decreases patients’ quality of life. The autonomic nervous system (ANS) is crucial to healthy sleep, and the transition from wake to sleep produces the largest shift in autonomic activity we experience every day. For patients with MS, the ANS is often impaired. The relationship between the ANS and perceived sleep quality in patients with MS remains elusive. Objective: In this study, we aim to quantify the impact of the ANS and MS on perceived sleep quality. Methods: We monitored 77 participants over 2 weeks using an arm-worn wearable sensor and a custom smartphone app. Besides recording daily perceived sleep quality, we continuously recorded participants’ heart rate (HR) and HR variability on a per-second basis, as well as stress, activity, and the weather (20,700 hours of sensor data). Results: During sleep, we found that reduced HR variability and increased motion led to lower perceived sleep quality in patients with MS (n=53) as well as the age- and gender-matched control group (n=24). An activated stress response (high sympathetic activity and low parasympathetic activity) while asleep resulted in lower perceived sleep quality. For patients with MS, an activated stress response while asleep reduced perceived sleep quality more heavily than in the control group. Similarly, the effect of increased stress levels throughout the day is particularly severe for patients with MS. For patients with MS, we found that stress correlated negatively with minimal observed HR while asleep and might even affect their daily routine. We found that patients with MS with more severe impairments generally recorded lower perceived sleep quality than patients with MS with less severe disease progression. Conclusions: For patients with MS, stress throughout the day and an activated stress response while asleep play a crucial role in determining sleep quality, whereas this is less important for healthy individuals. Besides ensuring an adequate sleep duration, patients with MS might thus work to reduce stressors, which seem to have a particularly negative effect on sleep quality. Generally, however, sleep quality decreases with MS disease progression.


  • Top Cited Papers
    Open Access

    Modeling multiple sclerosis using mobile and wearable sensor data

    by Shkurta Gashi, Pietro Oldrati, Max Moebus, Marc Hilty, Liliana Barrios, Firat Ozdemir, PHRT Consortium, Veronika Kana, Andreas Lutterotti, Gunnar Rätsch, et al.

    Multiple sclerosis (MS) is a neurological disease of the central nervous system that is the leading cause of non-traumatic disability in young adults. Clinical laboratory tests and neuroimaging studies are the standard methods to diagnose and monitor MS. However, due to infrequent clinic visits, it is fundamental to identify remote and frequent approaches for monitoring MS, which enable timely diagnosis, early access to treatment, and slowing down disease progression. In this work, we investigate the mostreliable,clinically useful, andavailablefeatures derived from mobile and wearable devices as well as their ability to distinguish people with MS (PwMS) from healthy controls, recognize MS disability and fatigue levels. To this end, we formalize clinical knowledge and derive behavioral markers to characterize MS. We evaluate our approach on a dataset we collected from 55 PwMS and 24 healthy controls for a total of 489 days conducted in free-living conditions. The dataset containswearable sensor data– e.g., heart rate – collected using an arm-worn device,smartphone data– e.g., phone locks – collected through a mobile application,patient health records– e.g., MS type – obtained from the hospital, andself-reports– e.g., fatigue level – collected using validated questionnaires administered via the mobile application. Our results demonstrate the feasibility of using features derived from mobile and wearable sensors to monitor MS. Our findings open up opportunities for continuous monitoring of MS in free-living conditions and can be used to evaluate and guide the effectiveness of treatments, manage the disease, and identify participants for clinical trials.


  • Open Access

    Meaningful digital biomarkers derived from wearable sensors to predict daily fatigue in multiple sclerosis patients and healthy controls

    by Max Moebus, Shkurta Gashi, Marc Hilty, Pietro Oldrati, Christian Holz


  • Top Cited Papers
    Open Access

    Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma

    by Reza Naghavian, Wolfgang Faigle, Pietro Oldrati, Jian Wang, Nora C. Toussaint, Yuhan Qiu, Gioele Medici, Marcel Wacker, Lena K. Freudenmann, Pierre-Emmanuel Bonté, et al.

    Microbial organisms have key roles in numerous physiological processes in the human body and have recently been shown to modify the response to immune checkpoint inhibitors1,2. Here we aim to address the role of microbial organisms and their potential role in immune reactivity against glioblastoma. We demonstrate that HLA molecules of both glioblastoma tissues and tumour cell lines present bacteria-specific peptides. This finding prompted us to examine whether tumour-infiltrating lymphocytes (TILs) recognize tumour-derived bacterial peptides. Bacterial peptides eluted from HLA class II molecules are recognized by TILs, albeit very weakly. Using an unbiased antigen discovery approach to probe the specificity of a TIL CD4+ T cell clone, we show that it recognizes a broad spectrum of peptides from pathogenic bacteria, commensal gut microbiota and also glioblastoma-related tumour antigens. These peptides were also strongly stimulatory for bulk TILs and peripheral blood memory cells, which then respond to tumour-derived target peptides. Our data hint at how bacterial pathogens and bacterial gut microbiota can be involved in specific immune recognition of tumour antigens. The unbiased identification of microbial target antigens for TILs holds promise for future personalized tumour vaccination approaches.


  • Open Access

    Cognitive fatigability assessment test (cFAST): Development of a new instrument to assess cognitive fatigability and pilot study on its association to perceived fatigue in multiple sclerosis

    by Liliana Barrios, Rok Amon, Pietro Oldrati, Marc Hilty, Christian Holz, Andreas Lutterotti

    Background: Fatigue is a common symptom of many diseases, including multiple sclerosis. It manifests as a cognitive or physical condition. Fatigue is poorly understood, and effective therapies are missing. Furthermore, there is a lack of methods to measure fatigue objectively. Fatigability, the measurable decline in performance during a task, has been suggested as a complementary method to quantify fatigue. Objective: To develop a new and objective measurement of cognitive fatigability and investigate its association with perceived fatigue. Methods: We introduced the cognitive fatigability assessment test (cFAST), a novel smartphone-based test to quantify cognitive fatigability. Forty-two people with multiple sclerosis (23 fatigued and 19 non-fatigued, defined by the Fatigue Scale for Motor and Cognitive Functions) took part in our validation study. Patients completed cFAST twice. We used t-tests, Monte Carlo sampling, and area under the receiver operating characteristic curves to evaluate our approach using two sets of proposed metrics. Results: When classifying fatigue, our fatigability metric Δresponse time has a mean area under the receiver operating characteristic curve of 0.74 (95% CI 0.64–0.84), making it the best performing metric for this task. Furthermore, Δresponse time shows a statistically significant difference between the fatigued and non-fatigued groups (t = 2.27, P = .03). Particularly, cognitively-fatigued patients decline in performance, while non-fatigued patients do not. Conclusions: We introduce cFAST, a new instrument to quantify cognitive fatigability. Our pilot study provides evidence that cognitive fatigability assessment test produces a quantifiable drop in cognitive performance in a short period. Furthermore, our results indicate that cFAST may have the potential to serve as a surrogate for subjective cognitive fatigue. cFAST is significantly shorter than the existing fatigability assessments and does not require specialized equipment. Thus, it could enable frequent and remote monitoring, which could substantially aid clinicians in better understanding and treating fatigue.


  • Open Access

    Continuous monitoring with wearables in multiple sclerosis reveals an association of cardiac autonomic dysfunction with disease severity

    by Marc Hilty, Pietro Oldrati, Liliana Barrios, Tamara Müller, Claudia Blumer, Magdalena Foege, PHRT consortium, Christian Holz, Andreas Lutterotti

    Background: Dysfunction of the autonomic nervous system is common in multiple sclerosis patients, and probably present years before diagnosis, but its role in the disease is poorly understood. Objectives: To study the autonomic nervous system in patients with multiple sclerosis using cardiac autonomic regulation measured with a wearable. Methods: In a two-week study, we present a method to standardize the measurement of heart rate variability using a wearable sensor that allows the investigation of circadian trends. Using this method, we investigate the relationship of cardiac autonomic dysfunction with clinical hallmarks and subjective burden of fatigue and autonomic symptoms. Results: In 55 patients with multiple sclerosis and 24 healthy age- and gender-matched controls, we assessed the cumulative circadian heart-rate variability trend of two weeks. The trend analysis revealed an effect of inflammation ( P = 0.0490, SMD = -0.5466) and progressive neurodegeneration ( P = 0.0016, SMD = 1.1491) on cardiac autonomic function. No association with subjective symptoms could be found. Conclusions: Trend-based heart rate variability measured with a wearable provides the opportunity for unobtrusive long-term assessment of autonomic functions in patients with multiple sclerosis. It revealed a general dysregulation in patients with multiple sclerosis.